MorgentalerA.Testosterone and Prostate Cancer: An Historical Perspective on a Modern Myth. Eur Urol, 2006; 50(5):935–939.
2.
NieschlagE.Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf), 2006; 65(3):275–281.
3.
LiuP.Y., DeathA.K., HandelsmanD.J.Androgens and cardiovascular disease. Endocr Rev, 2003; 24(3):313–340.
4.
WuF.C., von EckardsteinA.Androgens and coronary artery disease. Endocr Rev, 2003; 24(2):183–217.
5.
NieschlagE., NieschlagS., et al.Lifespan and testosterone. Nature, 1993; 366(6452):215.
6.
TibblinG., AdlerberthA., et al.The pituitary-gonadal axis and health in elderly men: a study of men born in 1913. Diabetes, 1996; 45(11):1605–1609.
7.
LaaksonenD.E., NiskanenL., et al.Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care, 2004; 27(5):1036–1041.
8.
MullerM., GrobbeeD.E., et al.Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab, 2005; 90(5):2618–2623.
9.
SelvinE., FeinleibM., et al.Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care, 2007; 30(2):234–238.
10.
KapoorD., MalkinC.J., et al.Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf), 2005; 63(3):239–250.
11.
MakhsidaN., ShahJ., et al.Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol, 2005; 174(3):827–834.
12.
RodriguezA., MullerD.C., et al.Aging, Androgens, and the Metabolic Syndrome in a Longitudinal Study of Aging. J Clin Endocrinol Metab, 2007; 92(9):3568–3572.
13.
YesilovaZ., OktenliC., et al.Evaluation of insulin sensitivity in patients with Klinefelter's syndrome: a hyperinsulinemic euglycemic clamp study. Endocrine, 2005; 27(1):11–15.
14.
PitteloudN., MoothaV.K., et al.Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care, 2005; 28(7):1636–1642.
15.
YialamasM.A., DwyerA.A., et al.Acute Sex Steroid Withdrawal Reduces Insulin Sensitivity in Healthy Men with Idiopathic Hypogonadotropic Hypogonadism. J Clin Endocrinol Metab, 2007; 92(11):4254–4259.
16.
GouldD.C., KirbyR.S., et al.Hypoandrogen-metabolic syndrome: a potentially common and underdiagnosed condition in men. Int J Clin Pract, 2007; 61(2):341–344.
17.
RohrmannS., SmitE., et al.Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond), 2005; 29(3):310–316.
18.
KasturiS., RussellS., et al.Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep, 2006; 7(4):288–292.
19.
McVaryK.Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int, 2006; 97(Suppl 2):23–28: discussion 44-5.
20.
RosenR.C.Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia. Curr Opin Urol, 2006; 16(1):11–19.
VagueJ.La differenciation sexuelle, facteur determinant des form de l’obesite Presse. Med, 1947; 30.
27.
BjörntorpP.Abdominal obesity and the metabolic syndrome. Ann Med, 1992; 24(6):465–468.
28.
BjörntorpP.Visceral obesity: a “civilization syndrome”. Obes Res, 1993; 1(3):206–222.
29.
RoemmichJ.N., ClarkP.A., et al.Alterations in growth and body composition during puberty: III. Influence of maturation, gender, body composition, fat distribution, aerobic fitness, and energy expenditure on nocturnal growth hormone release. J Clin Endocrinol Metab, 1998; 83(5):1440–1447.
30.
OnatA., HergencG., et al.Serum sex hormone-binding globulin, a determinant of cardiometabolic disorders independent of abdominal obesity and insulin resistance in elderly men and women. Metabolism, 2007; 56(10):1356–1362.
31.
KatznelsonL., RosenthalD.I., et al.Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. AJR Am J Roentgenol, 1998; 170(2):423–427.
32.
SmithM.R., FinkelsteinJ.S., et al.Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab, 2002; 87(2):599–603.
33.
SmithR.M., NathanL.H.Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab, 2006; 91:1305–1308.
34.
ZmudaJ.M., CauleyJ.A., et al.Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol, 1997; 146(8):609–617.
35.
TsaiE.C., BoykoE.J., et al.Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord, 2000; 24(4):485–491.
36.
RosmondR., WalleriusS., et al.A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern. J Intern Med, 2003; 254(4):386–390.
37.
KaufmanJ.M., VermeulenA.The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev, 2005; 26(6):833–876.
38.
NormanR.J., DewaillyD., et al.Polycystic ovary syndrome. Lancet, 2007; 370(9588):685–697.
39.
TchernofA., PoehlmanE.T.Effects of the menopause transition on body fatness and body fat distribution. Obes Res, 1998; 6(3):246–254.
